Enorama Pharma AB (publ) filed its Annual on Jun 09, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.57 SEK | +7.08% | -1.15% | -17.10% |
05-22 | Enorama Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
02-28 | Intervacc's Acting CEO Assumes Role Permanently | MT |
1st Jan change | Capi. | |
---|---|---|
-17.10% | 10.09M | |
+17.55% | 43.26B | |
+17.05% | 21.6B | |
+21.10% | 15.93B | |
+24.06% | 15.1B | |
+55.12% | 12.95B | |
-0.05% | 6.79B | |
-16.06% | 6.29B | |
+19.77% | 6.04B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- ERMA Stock
- News Enorama Pharma AB
- Enorama Pharma AB Auditor Raises 'Going Concern' Doubt